Abstract
Double filtration plasmapheresis was approved in April 2008 in Japan for the retreatment of chronic hepatitis C patients with genotype 1b and high viral loads, whose hepatitis C virus was not eradicated by previous pegylated IFN plus ribavirin combination therapy. Eight patients with non-sustained virological response (SVR) to the combination therapy were enrolled in this study, and early viral dynamics were assessed. DFPP plus consecutive intravenous IFN-β treatment for 4 weeks reduced the viral load by 1 log in 2 of 5 (40%) patients 24 hours and 1 week after the start of treatment, and in 4 of 5 (80%), and by 2 log in 2 of 5 (40%) 4 weeks after the start of treatment. The present study suggests that DFPP plus consecutive intravenous IFN-β treatment for 4 weeks appears to be a promising treatment for non-SVR patients with genotype 1b and high viral load previously treated with PEG-IFN+RBV therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
